Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) Times Interest Earned (2020 - 2022)

Historic Times Interest Earned for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to -$928119.2.

  • Inhibikase Therapeutics' Times Interest Earned fell 41696255.1% to -$928119.2 in Q1 2022 from the same period last year, while for Dec 2022 it was -$3.6 million, marking a year-over-year decrease of 48909522.26%. This contributed to the annual value of -$741.16 for FY2021, which is 67316.52% down from last year.
  • As of Q1 2022, Inhibikase Therapeutics' Times Interest Earned stood at -$928119.2, which was down 41696255.1% from -$31908.0 recorded in Q4 2021.
  • Inhibikase Therapeutics' Times Interest Earned's 5-year high stood at -$52.08 during Q2 2020, with a 5-year trough of -$928119.2 in Q1 2022.
  • For the 3-year period, Inhibikase Therapeutics' Times Interest Earned averaged around -$109939.3, with its median value being -$222.54 (2021).
  • In the last 5 years, Inhibikase Therapeutics' Times Interest Earned tumbled by 20598.01% in 2021 and then crashed by 41696255.1% in 2022.
  • Quarter analysis of 3 years shows Inhibikase Therapeutics' Times Interest Earned stood at -$168.21 in 2020, then tumbled by 18869.2% to -$31908.0 in 2021, then plummeted by 2808.74% to -$928119.2 in 2022.
  • Its Times Interest Earned stands at -$928119.2 for Q1 2022, versus -$31908.0 for Q4 2021 and -$28478.0 for Q3 2021.